Overview

Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies

Status:
Unknown status

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

Recent clinical studies have shown that the combination of lapatinib and trastuzumab has superior antitumor activity compared to either single drug in both neoadjuvant and metastatic setting and is well tolerated. According to this evidence, the combination of lapatinib and trastuzumab today offers a valid chemotherapy-free option, primarily for patients with pre-treated HER2-positive MBC

Phase:

Phase 2

Details

Lead Sponsor:

Consorzio Oncotech

Collaborator:

Clinical Research Technology S.r.l.

Treatments:

Lapatinib
Trastuzumab